Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sold 10 contracts of Nov 2020 13.0 Put AUPH Market 0.98
However, it appears that the Market Makers changed the bid/ask range after my sale when through. Also, if you put in a limit order, in the past, mine limit orders have never went off. Today, the size of bid was 20 contracts, that disappeared after my sale. GL to you
Stocks Are Surging on Hopes for Another Stimulus Package -- Barrons.com
12:37 pm ET October 5, 2020 (Dow Jones) Print
By Teresa Rivas
Stocks are rising on Monday, as are positive Covid-19 tests at the White House. A widening lead by Democratic presidential candidate Joe Biden has some hoping that more stimulus and an uncontested election results could be ahead.
The Dow Jones Industrial Average is up 1.3%, the S&P 500 is 1.4% higher, and the Nasdaq Composite is gaining 1.7% at recent check.
Investors may be hoping that a wider lead for Biden suggests there will be less room for President Donald Trump's campaign to challenge the results, given that the he pointedly hadn't committed to accepting them in the past. (A contested election would likely put some strain on markets, many analysts say.)
Robert Teeter, a managing director of Silvercrest Asset Management, argues that the election is still a risk factor, and that "investors may be prudent to prepare for any disruptive outcome." That said, he doesn't think it will be the most important factor driving growth next year. "The most powerful influence will be the economic recovery's capacity to propel earnings growth in 2021 -- followed closely by low interest rates that will enable multiples to remain elevated."
As for individual stocks, DocuSign (DOCU) is up 5.2% following an upgrade from Morgan Stanley, given the prevalence of online signatures during Covid-19.
Starbucks stock (SBUX) is up 1.7% to $88.03 after Oppenheimer raised its price target and called it an "actionable buy."
Tesla stock (TSLA) is up 2.2% to $424.39 amid conflicting analyst opinion.
Walmart stock (WMT) is up 0.9% to $141.75, helped by a price target increase from Telsey Advisory Group, which praised its sale of a majority stake in Asda.
Write to Teresa Rivas at teresa.rivas@barrons.co
The short answer is probably, Verizon is a strong enough partner for continued growth; but they are hardly Inseego's only partner.
Here's a list of Inseego's partners, at least earning report, the CEO,
"Dan the Man" promised we'd be hearing about more rollouts before next earnings reports. Time is running short on that promise, yet, INSG can have their work done and can be awaiting the launch, Dan made it clear that INSG has zero control over when their partners launch 5G, he did conment that once a partner does go online, INSG has had zero issues.
Damn if I know why we're selling in the cellar.
Here's the list of partners:
https://www.inseego.com/partners/?gclid=CjwKCAjwiOv7BRBREiwAXHbv3If4PzfWl11rbhvuUfqhdNmABK8iKW0BjXuFOciNJO2Y8jlw-LXushoCUUYQAvD_BwE
Doc,
I believe that Dan Mondor is "Old School" and doesn't "toot" his own horn whenever he gets an urge too. I also believe he's limited in announcing when other companies are going online with 5G, my guess, that's due to individual contracts. He does make announcements about the future with every earnings report, but doesn't go out on a limb and give glossy guidance. He did bring this dude to the Board who's been involved in the financial markets, lets see if he helps at all. We do need exposure.
I share your concerns about our share price, INSG seems to drop when the market dislikes tech, however, INSG has never truly appreciated, even while the business has grown. Like you, I'm puzzled as to why.
Best of Luck,
Slim
Inseego Corp. Appoints Christopher Lytle to Board of Directors
4:15 pm ET October 1, 2020 (BusinessWire) Print
Inseego Corp. (Nasdaq: INSG) (the "Company"), a pioneer in 5G and intelligent IoT device-to-cloud solutions, today announced that its Board of Directors approved an increase in the number of authorized directors on the Board from five to six and appointed Christopher Lytle to the Board to fill the newly created directorship, effective October 1, 2020.
"On behalf of Inseego and the Board of Directors, I am pleased to welcome Chris Lytle to Inseego's board," said Dan Mondor, chairman and CEO of Inseego. "Chris was instrumental in helping set the Company's strategic direction as our former Chief Strategy Officer, followed by EVP of our Enterprise SaaS business, and as a consultant including his most recent role as Head of Government Affairs. As we add a differentiated software stack to our 5G products, Chris adds strength to the board around key edge compute and cloud-native applications. We look forward to Chris's contributions to our strategic direction and continued efforts of increasing value to our shareholders."
Mr. Lytle is a proven leader with extensive experience providing strategic vision to SaaS-based businesses and investing in technology companies. He has been serving in a consulting capacity as Inseego's Head of Government Affairs since April 2020 and has been providing strategic consulting services to the Company since 2018. Mr. Lytle previously served as the Company's Chief Strategy Officer and Executive Vice President of Enterprise SaaS Solutions from August 2017 to October 2018. Prior to joining Inseego, Mr. Lytle was President of Cavulus, a privately-held SaaS-based technology provider in the healthcare industry. Before joining Cavulus, Mr. Lytle was a Managing Director at Morgan Stanley and previously was Lead Portfolio Manager of RCL Capital, a hedge fund focused on small and mid-cap telecom and wireless technology businesses. He also recently became Chairman of Prolifiq, a leading cloud-native provider of sales- enablement applications to Salesforce customers. Mr. Lytle holds a Bachelor of Arts degree in Economics from Lafayette College.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry pioneer in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband and fixed wireless access (FWA) solutions incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company's patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
(C)2020. Inseego Corp. All rights reserved. The Inseego name and logo are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001006108/en/
SOURCE: Inseego Corp.">
Media contact:
Anette Gaven
Tel: +1 (619) 993-3058
Email: Anette.Gaven@inseego.com
Or
Investor Relations contact:
Joo-Hun Kim, MKR Group
Tel: +1 (212) 868-6760
Email: joohunkim@mkrir.com
Wrangler, do you have access to these reports? Have you heard anything about QCOM buying INSG?
Vehicle Telematics Market to Reach USD 144.47 Billion by 2027; Recent Technological Advances in Software-based Telematics to Aid Growth, says Fortune Business Insights(TM)
7:10 am ET September 29, 2020 (Globe Newswire) Print
The global vehicle telematics market size is projected to reach USD 144.47 billion by the end of 2027. The massive investments in software-based telematics and the increasing smartphone penetration will emerge in favor of market growth. The strict regulations associated with the use of telematics in several countries across the globe will emerge in favor of market growth. According to a report published by Fortune Business Insights, titled "Vehicle Telematics Market Size, Share & COVID-19 Impact Analysis, By Technology Type (Embedded, Tethered, and Integrated), By Sales Type (OEM and Aftermarket), By Vehicle Type (Passenger Cars and Commercial Vehicles) and Regional Forecasts, 2020-2027," the market was worth USD 115.49 billion in 2019 and will exhibit a CAGR of 8.4% during the forecast period 2020-2027.
Vehicle telematics is the combination of telecommunications and information technology tools. The concept can be used to track and monitor the location of vehicles along with several other large scale applications. Recent advances in telematics have enabled flexibility in the applications of the product, with massive investments contributing to the wider adoption of the concept across the world. The increasing adoption of the product across the world is consequential to the strict regulations associated with the use, implemented by government organizations across the world. The presence of several large scale companies will have a massive impact on the growth of the overall market in the coming years. Moreover, the increasing adoption of electric vehicles will also emerge in favor of market growth.
Get Sample PDF Brochure with Impact of COVID19:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/vehicle-telematics-market-102071
List of the Leading Companies Profiled in the Global Vehicle Telematics Market are:
-- Bosch Connected Devices and Solutions GmbH (Gerlingen, Germany)
-- Webfleet Solutions B.V. (Amsterdam, North Holland)
-- MiX Telematics (Florida, USA)
-- Trimble Inc. (California, USA)
-- Verizon (Atlanta, Georgia, USA)
-- Zonar Systems (Seattle, USA)
-- Octo Group S.p.A (London, England)
-- Inseego Corp. (San Diego, California, USA)
-- PTC (Boston. Massachusetts, USA)
-- Microlise Telematics Pvt. Ltd. (Nottingham, England)
-- Omnitracs (Dallas, Texas, USA)
-- Masternaut Limited. (London, England)
Decline in Vehicle Sales to Affect Growth of the Market During the Covid-19 Pandemic
The recent coronavirus outbreak has had a severe impact on several businesses across the world. The measures taken to curb the spread of the disease have affected several businesses across diverse industries. The practises that have adapted to minimize the effects of the pandemic have unfortunately affected most businesses in the SME category. With most companies implementing work-from-home policies, there has been a decrease in the use as well as sale of all types of vehicles. Additionally, the hesitancy in spending and restricted expenditures will affect the growth of the overall vehicle telematics market in the coming years.
Inquire Before Buying This Research Report:
https://www.fortunebusinessinsights.com/enquiry/queries/vehicle-telematics-market-102071
Constant Product Innovations will Provide Impetus to Market Growth
The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing product innovations has had the highest impact on market growth. With most companies focusing on introducing innovative products, there is a healthy market competition across the globe. The presence of several large scale manufacturers will subsequently influence the growth of the market in the coming years. In September 2017, Goodyear announced the launch of new telematics fleets. The company introduced smart tire solutions for semi-autonomous electric vehicle fleets, a step that is consequential to the rising demand for telematics across the world. The company has a strong brand presence and this concept will help the company widen its customer range across the globe.
North America to Emerge Dominant; Increasing Production of Commercial Vehicles will Bode well for Market Growth
The report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The efforts taken to maximize the use of sustainable energy, accounting to rising environmental concerns, will bode well for the growth of the regional market.
The market in Asia Pacific will also rise considerably owing to the presence of several large scale companies, along with the increasing use of electric vehicles, coupled with the adoption of telematics in electric vehicles. As of 2019, the market in North America was worth USD 35.14 billion and this value is projected to rise at a considerable pace in the coming years.
Browse Detailed Summary of Research Report With TOC:
https://www.fortunebusinessinsights.com/vehicle-telematics-market-102071
Detailed Table of Content:
-- Introduction
-- Research Scope
-- Research Scope
-- Market Segmentation
-- Research Methodology
-- Definitions and Assumptions
-- Executive Summary
-- Market Dynamics
-- Market Drivers
-- Market Drivers
-- Market Restraints
-- Market Opportunities
-- Key Insights
-- Merger, Acquisitions, and Partnerships
-- Merger, Acquisitions, and Partnerships
-- Distributor Analysis - For Major Players
-- Growth and Penetration Analysis
-- Porter's Five Forces Analysis
-- PEST Analysis
-- COVID-19 Impact
-- Global Vehicle Telematics Market Analysis, Insights and Forecast, 2016-2027
-- Key Findings / Summary
-- Key Findings / Summary
-- Market Analysis, Insights and Forecast - By Vehicle Type
-- Passenger Cars
-- Passenger Cars
-- Commercial Vehicles
-- Market Analysis, Insights and Forecast - By Technology Type
-- Embedded
-- Embedded
-- Tethered
-- Integrated
-- Market Analysis, Insights and Forecast - By Sales Type
-- OEM
-- OEM
-- Aftermarket
-- Market Analysis, Insights and Forecast - By Region
-- North America
-- North America
-- Europe
-- Asia pacific
-- Rest of the World
TOC Continued...!
Key Industry Development:
December 2019: Octo announced that it has completed the acquisition of Nebula Systems. Through this acquisition, the company will look to enhance its diagnostic solutions associated with vehicle telematics.
Get your Customized Research Report:
https://www.fortunebusinessinsights.com/enquiry/customization/vehicle-telematics-market-102071
Have a Look at Related Research Insights:
Electric Vehicle Telematics Market Size, Share & Industry Analysis, By Type (embedded, retrofitted), By Market (OEMs, aftermarket), By Application (safety & security, entertainment, information & navigation, diagnostics, others), and Regional Forecasts, 2019-2026
Connected Car Market Size, Share & Industry Analysis, By Service (Mobility, Telematics, Infotainment, Driver Assistance), By Connectivity (Embedded, Tethered, Integrated), By Vehicle (Passenger Car, Light Commercial Vehicle, Heavy Commercial Vehicle), and Regional Forecasts, 2019-2026
About Us:
Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights(TM), we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights(TM)
LinkedIn | Twitter | Blogs
Read Press Release:
https://www.fortunebusinessinsights.com/press-release/global-vehicle-telematics-market-10224
https://ml.globenewswire.com/media/05408ba1-26b1-4fdd-8f48-1af4df373348/small/fbi-logo-tm-png.png
Cubbie might see her 200 before year's end. I live to far away to get Walmart Plus grocery delivery, but in the long run, this is going to help both Walmart's and BYND
I didn't see this kind of a run, has to be short covering, too. MCD still has to make up their minds on what to do.
Introducing the Inseego 5G MiFi(R) M2000 mobile hotspot for global markets
8:15 am ET September 9, 2020 (BusinessWire) Print
Inseego Corp. (Nasdaq: INSG), a pioneer in 5G and intelligent IoT device-to-cloud solutions, today unveiled the first commercially available 5G MiFi(R) mobile hotspot built on second-generation 5G technology. The Inseego MiFi M2000 series mobile hotspot delivers blazing-fast speeds and seamless connectivity across 5G mmWave, sub-6 and 4G LTE networks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200909005602/en/
"After leading the way with our first-generation 5G MiFi mobile hotspot last year, we're raising the bar once again with our second-generation 5G MiFi M2000 series for mobile operator networks worldwide. We're opening the door to many powerful new applications -- across every industry," said Inseego Chairman and CEO Dan Mondor. "Our customers are looking for sleek and compact devices built for productivity, performance and security from the ground up. The MiFi M2000 is a plug-and-play gateway allowing users to experience the power of 5G with their existing laptops, tablets and smartphones."
Groundbreaking technology meets breakthrough performance
Combining the Qualcomm(R) Snapdragon(R) X55 5G Modem-RF System with Inseego's proprietary advanced RF technology design, the MiFi M2000 delivers data speeds over 2 Gbps* in mmWave bands and gigabit-plus* speeds in sub-6 GHz bands. It also supports new applications requiring the responsiveness and ultra-low latency that 5G technology enables.
With support for Dynamic Spectrum Sharing (DSS**), which allows 5G to operate in 4G spectrum, the MiFi M2000 enables users to enjoy the benefits of 5G across a wide area. And with seamless fallback to the most advanced 4G LTE, it delivers the best available combination of 5G and 4G speed, performance, and coverage.
Stop the bottlenecks with Wi-Fi 6
The MiFi M2000 uses efficient, simultaneous, dual-band Wi-Fi 6 technology which offers greater capacity and up to 4x faster speeds for connected devices compared to Wi-Fi 5. This empowers users to connect more devices at the same time, without compromising performance or sacrificing battery life. It securely connects up to 30 devices over Wi-Fi along with the option for a direct tethered connection using the USB-C port.
Advanced device management
Mobile device management empowers IT departments to manage devices out in the field with tools such as device settings configuration, GPS location, and device logs.
Enterprise-grade security
Designed and developed in the USA, the Inseego MiFi M2000 series provides multiple layers of protection with the latest WPA 3 Wi-Fi security protocol, advanced encryption, hacker prevention, password protection, Guest Wi-Fi network, VPN pass-through and Open VPN.
All-day power
Do more without worrying about battery life. The removeable battery delivers connectivity all day* long and is designed with the Qualcomm Quick Charge(TM) technology so users can recharge rapidly. Road warriors can enjoy peace of mind when it comes to keeping their devices connected no matter where they go since the MiFi M2000 can also be used as a battery bank to charge a phone, tablet or other connected device. An 8500mAh accessory battery (sold separately) provides added power.
Turn any Wi-Fi enabled device into a 5G powerhouse, easily
With a large 2.4" touchscreen color display and simple menus supporting multiple languages, the plug-and-play MiFi M2000 makes it easy to connect laptops, smartphones and tablets and other Wi-Fi enabled devices, view important information and protect data.
Light and compact
Sleek and portable, the lightweight MiFi M2000 fits easily into a pocket, purse or backpack.
Weight: 210g (7.4oz) Dimensions: 150 x 70 x 17.9mm (5.9 x 2.8 x 0.7in)
Push the boundaries with 5G
From data-hungry consumers to remote workers to cutting-edge enterprise applications, the MiFi M2000 provides ultra-fast, secure, reliable 5G connectivity for a world of exciting new applications that demand low latency and exponential capacity in the areas of healthcare, emergency response, manufacturing, education, entertainment and other areas, including:
work-from-home employees, travelers, satellite offices, kiosks and other business needs educators and students needing secure and reliable internet access for distance learning government employees and financial institutions requiring maximum security and privacy - both now and in the future enterprise networks (including private LTE/5G networks in the CBRS band)
Availability
The Inseego MiFi M2000 series will be coming to market through mobile network operators in select markets in North America, EMEA and Asia Pacific.
*Actual speeds and coverage may vary. Battery life and charge time may vary depending on the number of connected devices and activity.
** DSS is initially supported through an automatic firmware update
MEDIA: To learn more about Inseego 5G solutions or schedule an executive interview, please contact Inseego@GoDriven360.com.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry pioneer in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband and fixed wireless access (FWA) solutions incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company's patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. Inseego is headquartered in San Diego, California with offices worldwide. www.inseego.com
(C)2020. Inseego Corp. All rights reserved. The Inseego name and logo are trademarks of Inseego Corp. MiFi is a registered trademark of Inseego Corp. in the United States and other countries. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
Qualcomm Snapdragon, Qualcomm Quick Charge, and Qualcomm FastConnect are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
Qualcomm, Snapdragon, Quick Charge and FastConnect are trademarks or registered trademarks of Qualcomm Incorporated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005602/en/
SOURCE: Inseego Corp.">
Media contact:
Anette Gaven
Tel: +1 (619) 993-3058
Email: Anette.Gaven@inseego.com
Or
Investor Relations contact:
Joo-Hun Kim, MKR Group
Tel: +1 (212) 868-6760
Email: joohunkim@mkrir.com
Ganz, this wasn't the type of fire that I had in mind, but the day is still young.
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome
Download as PDF
September 28, 2020
- Voclosporin ophthalmic solution (VOS) results on track to be reported in the fourth quarter of 2020 -
- Study builds on positive head-to-head data with approved treatment reported in prior Phase 2a study -
- Dry eye syndrome is a chronic autoimmune disorder affecting quality of life for millions in the U.S. -
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).
“Despite the challenges posed by the ongoing viral pandemic, our clinical operations team at Aurinia has maintained executional excellence by completing the treatment phase of our major clinical trial assessing VOS in this common chronic autoimmune disorder, which affects more than 16 million people in the United States,” said Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Based upon the striking efficacy results observed with VOS in our head-to-head exploratory study against 0.05% cyclosporine, we are excited to see the results of this clinical trial which aims to fulfill a number of regulatory requirements typically required by the FDA for this indication.”
The AUDREY Phase 2/3 DES study is evaluating VOS via a randomized, double-masked, vehicle-controlled, dose ranging study evaluating efficacy and safety in subjects with DES compared to formulation. A total of 509 subjects were enrolled. The study consists of four arms with a 1:1:1:1 randomization schedule, patients received either 0.2% VOS, 0.1% VOS, 0.05% VOS or vehicle, dosed twice daily for 12 weeks. The primary outcome measure for the study is the proportion of subjects with a 10mm improvement in Schirmer’s Tear Test (STT) at four weeks. Secondary outcome measures include STT at 12 weeks and other time points, Fluorescein Corneal Staining (FCS) at multiple time points, change in eye dryness, burning/stinging, itching, photophobia, eye pain and foreign body sensation at multiple time points, change in Symptom Assessment in Dry Eye (SANDE) score at multiple time points, and additional safety endpoints.
In January of 2019, Aurinia reported that although VOS (voclosporin 0.2%) administered twice daily did not meet the primary endpoint of drop discomfort at one-minute, it was superior to Restasis® (0.05% cyclosporine A) administered twice daily in all objective endpoints including FCS and STT. This statistical superiority was seen as quickly as two weeks. Additionally, voclosporin was given at four times the dose of cyclosporine with no additional drop discomfort as measured by the drop discomfort scores at one and five minutes after application. Based on these data the Company has gained confidence that VOS represents a potential best-in-class calcineurin inhibitor in ophthalmic indications. This head-to-head study against the market leader was the first study that has ever shown treatment superiority vs. an active comparator in a double-blind randomized fashion.
Top-line results from the AUDREY clinical study are expected to be reported during the fourth quarter of 2020.
About voclosporin ophthalmic solution (VOS)
VOS is an aqueous, preservative free nanomicellar solution intended for use in the treatment of DES. Voclosporin is a potentially best-in-class calcineurin inhibitor (CNI) that has been shown to have a more predictable pharmacokinetic and pharmacodynamic relationship, increase in potency (versus cyclosporine) and an improved metabolic profile compared to legacy CNIs. Calcineurin inhibition is a validated mechanism for the treatment of ocular surface diseases. Positive Phase 2 results demonstrated that VOS 0.2% administered twice daily was clinically and statistically superior to 0.05% cyclosporine A (Restasis®) administered twice daily across all objective endpoints over four weeks.
About DES
Dry eye syndrome (DES) is characterized by irritation and inflammation that occurs when the eye’s tear film is compromised by reduced tear production, imbalanced tear composition, or excessive tear evaporation. The impact of DES ranges from subtle, yet constant eye irritation to significant inflammation and scarring of the eye’s surface. Discomfort and pain resulting from DES can reduce quality of life and cause difficulty reading, driving, using computers and performing daily activities. DES is a chronic disease estimated to affect more than 16 million people in the United States. There are multiple FDA approved therapies for the treatment of dry eye; however, there is opportunity for potential improvements in the effectiveness, tolerability and onset of action.
About Aurinia
Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the potential treatment of lupus nephritis and evaluating voclosporin ophthalmic solution (VOS) in a Phase 2/3 study for the treatment of dry eye syndrome. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.
Forward-Looking Statements
Certain statements made in this press release may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements regarding: expected timing of top-line results from the AUDREY clinical trial during the fourth quarter of 2020; potential results from the AUDREY clinical trial replicating the efficacy measures observed in the exploratory Phase 2 VOS study in 2019; that DES is estimated to affect more than 16 million people in the United States; and voclosporin and VOS being potentially best-in-class CNIs; there is opportunity for potential improvements in the effectiveness, tolerability and onset of action in therapies to treat DES. It is possible that such results or conclusions may change based on further analyses of these data. Words such as “anticipate”, “will”, “believe”, “estimate”, “expect”, “intend”, “target”, “plan”, “goals”, “objectives”, “may” and other similar words and expressions, identify forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: third party service providers and patients completing matters relating to the AUDREY clinical trial in a manner consistent with prior actions; the size of the DES market; the results of Aurinia’s clinical trials being accurate. Even though management of Aurinia believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate.
Forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aurinia to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Such risks, uncertainties and other factors include, among others, the following: difficulties, delays, or failures we may experience in the conduct of our clinical trial; clinical trial results may not be accurate; we may not be able to reproduce the results of our Phase 2 clinical study for VOS in our AUDREY Phase 2/3 clinical trial; the size of the DES market in the United States may not be as large as estimated. Although we have attempted to identify factors that would cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actual results, performances, achievements or events to not be as anticipated, estimated or intended. Also, many of the factors are beyond our control. There can be no assurance that forward-looking statements or information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, you should not place undue reliance on forward-looking statements or information.
Except as required by law, Aurinia will not update forward-looking information. All forward-looking information contained in this press release is qualified by this cautionary statement. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business can be found in Aurinia’s most recent Annual Information Form available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar.
We seek safe harbour.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005148/en/
Investor & Corporate Contact:
Glenn Schulman, PharmD, MPH
Corporate Communications, Aurinia
gschulman@auriniapharma.com
Media Contact
Stefan Riley
Ten Bridge Communications
stefan@tenbridgecommunications.com
Source: Aurinia Pharmaceuticals Inc.
Released September 28, 2020
Hi JL,
I believe that Mondor could care less about share price, I get the impression from the earnings reports that he feels he's got enough money to do what he wants to do with the company and once all the pieces fall into place, the share price will response.
I tried to get myself invited to an analysis only meeting in NYC, I introduced myself to IR and just asked for a pass, I wasn't granted one. I thought that was rather rude, I wouldn't have taken up anyone's time, I would have just been there to hear what he had to say.
Also, Verizon is advertising the living hell out of 5G up here, if Mondor wanted to move the share price, he could easily produce an add that states that Inseego is what gets you onto Verizon's 5G network, but once again, he doesn't.
Mondor is on seriously good terms with his Bond buyer, I've wondered about the possibilities of some kind of a insider takeover, it would just be our kind of luck.
Take Care,
Slim
15, shitttttttttttttttttttt
Ganz, I think we'll get an update about DES soon, I believe Management had said so at last earnings report. When we do, that will put a fire under the share price IMO.
Right now we are a bit range bound, once they report about DES, we'll run up and before the main event,
The FDA has granted Priority Review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 22, 2021.
TrueHeart,
Walmart needs to improve their "Amazon Prime-like delivery" currently, they only deliver within 7 miles of closest store, and IR said that was because they use sub contractors and they cannot be sure that they have AC to keep the food "fresh".
I told IR that if Amazon can figure it out, why can't Walmart's?
Answer, they are working on it.
Cramer Gives His Opinion On Chewy, Beyond Meat And More
8:02 am ET September 24, 2020 (Benzinga) Print
On CNBC's "Mad Money Lightning Round," Jim Cramer said Chewy Inc (NYSE: CHWY) is one of those high multiple stocks that is going to come down. At the same time, he likes the business very much. If you want to buy it now, you've got to take some pain, said Cramer.
Cramer would cost average in Chegg Inc (NYSE: CHGG), but he would do it only if it gets to $63.
Metlife Inc (NYSE: MET) is fine, said Cramer. He likes the yield, but that is all he can say. He is not a buyer of financials.
LyondellBasell Industries NV (NYSE: LYB) is a cyclical that is doing quite well, believes Cramer.
Beyond Meat Inc (NASDAQ: BYND) is ridiculously expensive and it is always going to be expensive because it is the future, said Cramer. He would buy some here and he would also buy some lower.
Cramer likes Inseego Corp (NASDAQ: INSG). He thinks it's doing very well and he would be a buyer if it gets below $10.
Magna International Inc. (NYSE: MGA) is the cheapest in the auto sector, believes Cramer. He likes the whole space and he thinks Magna is okay.
If I ran a large fund, I'd get AMRN off of my next Quarterly Report.
If I was on the Board of AMRN, I'd get Thero out of the door before the end of the day.
Everyone has an opinion on options, I personally do not give a hoot about the Greeks (other than Theta) however, others do, so you can sell on that fact. What I find most important about options is the spread and with AUPH, you have horrible spreads.
I couldn't remember how to spell Theta so I did look it up, here's an article about options if you care. GL
https://www.investopedia.com/terms/t/theta.asp
Where do you get this 1 Contract stuff from?
https://workhorse.com/
JK, you buying what this guy is selling.
It's getting chilly in NY, I'll bet it's getting cold in Ontario.
I sold 10 contracts of AUPH Oct 16 2020 13 Put and got 963.29 THey have a maintenance cost of $6,130.00. I sold mine about a month ago.
I like your trade, too. GL
UPDATE: Beyond Meat downgraded at JPMorgan as Impossible Foods snaps up share
1:18 pm ET September 21, 2020 (MarketWatch)
Share
Print
Tonya Garcia
Beyond Meat Inc.'s stock was downgraded to underweight from neutral at JPMorgan on Friday with analysts citing market share loss at grocery stores to its biggest competitor, Impossible Foods Inc.
Analysts also cited a pullback at restaurants, which are slower to add "complexity" to the menu during the COVID-19 pandemic.
JPMorgan has a $122 price target on Beyond Meat (BYND).
"In the long run, we believe Beyond Meat's growth opportunity is excellent, and we see the company as well managed with strong innovation and marketing plans," JPMorgan said. "But we believe Street estimates are a bit aggressive right now -- especially with chief rival Impossible Foods making strong inroads into Beyond Meat's on-shelf presence, and with many restaurants not adding menu items -- and we think the stock is ahead of itself."
Beyond Meat shares have nearly doubled for the year to date, up 96.6%, while the S&P 500 index has gained 0.6% for the period.
CFRA also downgraded Beyond Meat, to sell from hold, and cut its 12-month target to $100 from $130.
"Due to intensifying competition (both local and abroad) from other pure-play alternative meat companies and from larger packaged food companies, along with an expectation that Beyond Meat will continue to aggressively lower prices to reach price parity with traditional animal meat, we now find it difficult to believe Beyond Meat's margins will exceed its packaged food peers," Arun Sundaram wrote.
Impossible Foods, home of the Impossible Burger, has made gains on Beyond Meat, and done it fast, according to JPMorgan.
In just the past couple of months, Impossible Foods has expanded into Canadian retail (https://www.marketwatch.com/story/impossible-foods-expands-retail-to-canada-beyond-meat-brings-production-to-china-2020-09-08?mod=mw_quote_news), expanded its presence (https://www.marketwatch.com/story/beyond-meat-incogmeato-impossible-foods-up-ante-in-plant-based-meat-market-2020-08-27)at Kroger Co. (KR) nationwide , and secured $200 million (https://www.marketwatch.com/story/impossible-foods-gets-200-million-in-funding-2020-08-13) in funding. That's on top of $500 million in funding earlier this year.
See: Kraft Heinz stock upgraded twice with analysts upbeat about ongoing business transformation (https://www.marketwatch.com/story/kraft-heinz-stock-upgraded-twice-with-analysts-upbeat-about-ongoing-business-transformation-11600286425?mod=mw_quote_news)
Certainly, Beyond Meat isn't taking a rest. Just this week, the company expanded its lineup with Beyond Meatballs (https://www.marketwatch.com/story/beyond-meat-launching-plant-based-meatballs-this-week-2020-09-14?mod=mw_quote_news https://www.marketwatch.com/story/beyond-meat-to-launch-more-affordable-cookout-classic-product-at-walmart-and-target-stock-jumps-2020-06-17), the third launch this year after Beyond Sausage and Cookout Classic.
The company has tried to use the increased demand (https://www.marketwatch.com/story/impossible-foods-beyond-meat-see-spike-in-demand-as-coronavirus-wreaks-havoc-on-meat-supply-2020-05-05) during COVID-19 to its advantage, lowering prices (https://www.marketwatch.com/story/beyond-meat-offers-discounts-during-covid-19-to-take-advantage-of-higher-beef-prices-2020-08-05) on its product at a time when prices for beef have gone up.
Moreover, Beyond Meat is thinking beyond the U.S. grocer's shelf. The company has launched a direct-to-consumer operation that expands its reach. Impossible Foods launched a direct-to-consumer channel this summer as well.
Canaccord Genuity applauded the move from Beyond Meat as one that's expected to drive incremental revenue, deepen customer relationships and take advantage of the grocery shift to e-commerce.
Canaccord Genuity rates Beyond Meat shares hold with a $140 price target.
Beyond Meat has also brought its products to international markets like Brazil (https://www.marketwatch.com/story/beyond-meat-to-sell-its-plant-based-products-in-sao-paulo-marking-its-entrance-into-the-brazil-market-2020-07-15), and China, where Beyond Meat began selling at Shanghai grocery stores (https://www.marketwatch.com/story/beyond-meat-to-begin-sales-at-metro-china-locations-in-shanghai-starting-july-15-2020-07-14) over the summer, and is launching manufacturing facilities (https://www.marketwatch.com/story/beyond-meat-to-launch-manufacturing-facilities-in-china-2020-09-08?mod=mw_quote_news).
But these aren't the only two plant-based meat options, as the category continues to grow and expand into new products.
Kellogg Co.'s (K) Morningstar brand expanded its Incogmeato line of plant-based proteins with help from Walt Disney Co. (DIS) with the launch this week of Mickey Mouse shaped Chick'n Nuggets. The item is meant to appeal to families, and could create a market of lifelong plant-based meat eaters.
Read:Kellogg's Incogmeato partners with Disney for Mickey Mouse plant-based nuggets (https://www.marketwatch.com/story/kelloggs-incogmeato-partners-with-disney-for-mickey-mouse-plant-based-nuggets-11600344047?mod=mw_quote_news)
Dr. Praeger's launched beef and chicken plant-based sliders this week.
Meatless Farm (https://meatlessfarm.com/), a British-based food company, has landed in the U.S. And another global plant-based food company, Chile-based NotCo (https://notco.com/), is planning to bring its products to the U.S. after recently closing an $85 million round of funding. Among NotCo's investors is Bezos Expeditions (https://www.bezosexpeditions.com/), the investment group for Amazon.com Inc. (AMZN) founder Jeff Bezos.
Even with all of this activity in the category, some analysts remain upbeat about Beyond Meat's prospects. Baird initiated Beyond Meat at outperform earlier this month with a $160 price target.
Baird forecasts that Beyond Meat will end the year with enough manufacturing capability for more than $1 billion in gross revenue.
"We model substantial revenue growth over the next several years, driven by increasing distribution (domestically + internationally), increasing velocity per point of distribution, and introduction of new products," Baird analysts led by Ben Kallo wrote.
Don't miss:Pactiv Evergreen begins trading below IPO price and sinks further (https://www.marketwatch.com/story/pactiv-evergreen-begins-trading-below-ipo-price-and-sinks-further-2020-09-17?mod=mw_quote_news)
"Ultimately, Beyond Meat aims to capture traditional beef consumers, thereby gaining share in the meat market (as opposed to solely vegan/vegetarian consumers). With growing mainstream consumer acceptance/awareness of the Beyond brand, as well as growing interest in health, wellness, and sustainability, we expect Beyond products will continue to gain share."
-Tonya Garcia; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
September 21, 2020 13:18 ET (17:18 GMT)
Copyright (c) 2020 Dow Jones & Company
Yes, I am. I'm also selling puts, sometimes rolling them over to the following week. I hope you're right about 209 by years end.
Mets aren't going to make playoffs, boohoo
That's your opinion, I suggest you short it along with a lot of others that share your opinion.
Ganz, IMO, the Market Makers move this stock when options expire. Also, there's a lot (700+) of call buying north of current share price, 16 to 20 strike prices.
I'll bet someone knows when the company is going to be reporting about DES. I don't have the balls to be asking my new friend about DES, but I did think about it. GL, Slim
His opinion is exactly that, his opinion. Clearly, it holds more weight than mine, but history will prove him wrong. JPMorgan has GE at 4, folks that sold GE on that opinion are now looking at GE moving north of 7, nearly a double.
JPMorgan Downgrades Beyond Meat On Crazy Valuation
9:42 am ET September 18, 2020 (Benzinga) Print
Shares of Beyond Meat Inc (NASDAQ: BYND) are trading lower after JPMorgan turned bearish on the plant-based food maker.
The Beyond Meat Analyst: Ken Goldman downgraded Beyond Meat's stock from Neutral to Underweight with an unchanged $122 price target.
The Beyond Meat Thesis: Beyond Meat's stock gained nearly 200% since its 2020 lows and this gain is "above and beyond" any semblance of rationality, even for a "good company" like Beyond Meat.
Meanwhile, Beyond faces growing competition from rivals like Impossible Foods, the analyst notes. In fact, Impossible Foods is fresh off a $200 million Series G funding round and is looking to expand research and development, increase manufacturing, and beef-up its retail presence in the U.S. and beyond.
Meanwhile, Goldman said restaurants are hesitant to offer plant-based alternatives in favor of operating a more lean kitchen.
Beyond Meat will remain a hotly debated stock over the coming months and years. Other experts, analysts, and investors share similar concerns Goldman expressed related to the stock's valuation, especially after a triple-digit percentage gain. But others are looking towards the long-term picture where plant-based meat alternatives will dominate the food market.
For example, UBS modeled in an April note that the plant-based food market will reach $50 billion in sales in 2025. Beyond Meat's sales would grow at a 40% compounded annual growth rate.
BYND Price Action: Shares of Beyond Meat were trading lower by 4.7% Friday morning at $148.87.
Related Links:
Marjac, I understand it's your time I'm talking about, but you have a better understanding of what's going on with Amarin than Singer does, I'm with State, go for it!
He didn't say he hired an Investment Banker because he's honestly believes he can GIA in Europe. You know, I'm right, you know that, don't you? You know, you just don't want to admit it, but damn it, you know, he's going to GIA in Europe. That's what's going to happen.
Level with me, if anyone wanted to buy us out, they would have by now.
Hi Doc,
I agree with you that $12.62 (convertible rate) is a huge bump, but we'll get over it. Verizon has launched 5G in New York, there's all kinds of adds on TV about everything but INSG. I believe
Mondor is much more interested in running the company than worrying about share price, he is correct that a well run company will move the shares sooner or later.................in our case, it's going to be later.
Always the Best,
Slim
John Thero over at Amarin is a CPA that was at the right place at the right time, but man oh man, have you ever heard him speak. He's way over his head, and doesn't know it. Thero is over there, and this is Aurinia. You can tell me, Thero has one employee in Europe, and he's feels it's best for shareholder value to GIA, perhaps you can guess if he's a Dick, Prick or straight up Dickhead. For what it's worth, anyone taking a statin, should IMO, also be taking Vascepa.
ZZ, it should have been clear, that several of my posts were tongue in cheek, the fact that I received the answer to my question does move the man up, it's that simple.
If you recall, I wanted to start a dialogue with IR, I've accomplished that. Next year, after the FDA shindig, I'll get back in touch with my "buddy". If everyone is lucky, until then, I'll climb back under my rock.
Good Luck, to you.
I have a new friend, our company is planning on a GIA strategy, lets hope they get an offer they can not refuse. I'm thankful that Glenn answered honestly, I would have liked to have heard that after FDA approval, they were going to hire an Investment Banker before deciding on a launch of their own; they could hire an IB while PR'ing that they are planning a launch since they did just did the secondary and do have the money, but if they in fact, GIA, they'll need more money. IMO. Good Luck
Dear John,
Thanks for your email. For some reason your query went into the corporate spam folder so apologies for the delayed response. Aurinia submitted a New Drug Application for voclosporin to the FDA which was accepted for Priority Review with an anticipated PDUFA action date of January 22, 2021. Aurinia is currently preparing for the potential approval and launch of the first FDA-approved for a treatment for lupus nephritis. Let me know if you have any additional questions.
Best regards,
Glenn
Dr. Glenn Schulman, SVP of IR & Corp Comm
Aurinia Pharmaceuticals
gschulman@auriniapharma.com
It is your money, but I had AMRN shares that I had paid from 1-3 bucks per share, others higher, nevertheless, I rode those bad boys up to 26 and down to where they are today at 4.10. I've lost hundreds of thousands of dollars, depending on how many shares of AUPH you have, that can be you.
When you buy is important, when you sell can be just as important, in my current opinion, it's more important.
I believe most are overpaid; however, I'll pick on this prick now, but you'll see that I'm offering to go after different pricks next.
Please do note, I'm not delusional, I know they don't get two poops about us, less so now that they pulled that secondary and have money to burn.
Dear Mr. Schulman,
It's hard to get an answer from you, that's for sure! I'm not sure how many attempts I've taken, but it seems that you're way too busy to answer me. Please let me know, since you do work for me, you are aware of that; aren't you, you work for the shareholder, exactly what it is that you are doing that keeps you from addressing my issues, or any other shareholder's issues, for that matter?
I'm a bit concern that perhaps you aren't following my thought process, I've bought before the pandemic (which was your clue that I bought high) or at least before the market in general realized that Aurinia wasn't worth what I had paid for it, perhaps, that's because further shareholders had they tried to get an answer from Investor's Relation got the same thing that I got from you, zilch, nada, or a big fat goose egg.
Clearly, I'm not happy with your performance. Please tell me that you've been on holiday or maybe even paternity leave, something, anything; just don't let me believe you're ignoring shareholders.
Also Mr. Schulman, I'm done thanking you in advance for the time it's taking you to answering me, since you haven't been answering me. I'm just hoping that you do take the time to answer me for I will be perusing it with more senior Aurinia employees, again, I'll remind you, they too, work for the shareholders, just maybe they understand that they work for shareholders and possibly, they'll give me an honest answer. Time will tell.
Sincerely,
Jess, take a look at AMRN's stock price, I'm in a horrible mood that I don't see going away anytime soon; or said another way, it's my turn to piss people off and I have my aim on this dick
Investor Relations
Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
IR@auriniapharma.com
Walmart is owned by Sam's family, with a few retail owners thrown in to yap about this and that.
I believe that Walmart+ will help sell a lot of toys that people want to buy, just aren't all that interested in going to Walmart stores.
Beyond Meat Inc (NASDAQ: BYND) CEO Ethan Brown said Wednesday that the company’s push into international markets such as China hasn't been dampened by the COVID-19 pandemic.
What Happened: “When you see an obstacle like Covid, you don’t say you’re not going to do it, you say ‘How am I going to do it?’ and work on a solution,” Brown said in an interview with CNBC.
The chief executive appreciated the assistance of Micky Pant, former CEO of Yum China Holdings Inc (NYSE: YUMC), who now serves as a senior advisor to the plant-based protein company.
The two production facilities will be built in Jiaxing Economic & Technological Development Zone, near Shanghai, the company announced Tuesday.
Full production is expected to begin early next year. “I will work very hard to make sure that we’re not exporting American taste,” Brown told CNBC.
Why It Matters: Beyond shares have risen 9.8% so far this week with the news of expansion in China and nearly 83% on a year-to-date basis. Brown said in the interview he doesn't pay much attention to the market’s reaction.
The California-based company forged a retail partnership with Alibaba Group Holding Ltd (NYSE: BABA) in July to sell its Beyond Burger in China.
The company already offers its products in China through Starbucks Corporation (NASDAQ: SBUX) and Yum China restaurant chains such as KFC and Pizza Hut.
The lucrative Chinese market is also a target for Beyond’s rivals Impossible Foods and Zhenmeat.
Price Action: Beyond Meat shares closed 2.75% higher at $138.17 on Wednesday and fell 0.12% in the after-hours session.
Good one, I guess the Judges also gave him a robust answer.
Me too, but I had wished it said that he was relieved of all duties and escorted from the building.
Instead, they are going to put a mike in his hands which will pretty much escort everyone within hearing distance of him.
There's a $2070.00 maintenance requirement on just ten contracts of the AMRN Oct 16 2020 4 Put, so doing as you're suggesting is going to tie up a lot of money.
We'll see, I wouldn't put it past his abilities, "Old Marble Mouth" might be able to cut us in half.
How can the Board allow this to continue?